Plain-English translation of NCT06106945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new investigational drug called to see if it can help people with multiple myeloma, a cancer of blood cells. Researchers will study whether the medication works better when given alone or when combined with other existing cancer drugs. The goal is to find the right dose and determine how well this treatment works for patients who have already tried other therapies.
Multiple myeloma often comes back and can become resistant to standard treatments, especially in patients who have already tried several other therapies. This trial is exploring whether this new medication can offer a new option for people whose cancer has not responded to previous treatments.
You likely qualify if…
You likely don't qualify if…
You will join one of three study groups to receive either the new medication alone or combined with one or two other existing cancer drugs, taken at doses that researchers determine are safe. You will have multiple visits to the research center for blood tests, health evaluations, and monitoring of how well the treatment is working and what side effects you may experience. The study is designed to gradually increase doses in early phases and then expand to see how well the medication works in later phases.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States